The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of erlotinib plus tivantinib in patients with EGFR-mutation–positive NSCLC who failed in immediately previous EGFR-TKI therapy.
Tomonori Hirashima
No relevant relationships to disclose
Koichi Azuma
No relevant relationships to disclose
Nobuyuki Yamamoto
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Chugai Pharma
Toshiaki Takahashi
No relevant relationships to disclose
Makoto Nishio
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer; Taiho Pharmaceutical
Taizo Hirata
No relevant relationships to disclose
Kaoru Kubota
No relevant relationships to disclose
Kazuo Kasahara
No relevant relationships to disclose
Toyoaki Hida
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma; Kyowa Hakko Kirin
Hiroshige Yoshioka
Honoraria - Chugai Pharma
Kohei Suzuki
Employment or Leadership Position - Kyowa Hakko Kirin
Shiro Akinaga
Employment or Leadership Position - Kyowa Hakko Kirin
Kazuto Nishio
No relevant relationships to disclose
Tetsuya Mitsudomi
Consultant or Advisory Role - Chugai Pharma; Kyowa Hakko Kirin; Roche
Kazuhiko Nakagawa
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma